论文部分内容阅读
多发性硬化（MS）是一种慢性进展性疾病，可见躯体和心理功能障碍症状，对生活质量产生严重负面影响。生活质量是常用的患者报告结局（PRO）指标之一，可对疾病进行广泛和主观的评估，也可对治疗效果进行测评。Teri-PRO研究通过治疗满意度问卷调查了MS患者经特立氟胺治疗的整体满意度，结果显示MS患者在将注射用疾病修正治疗（DMT）药物转换为口服特立氟胺治疗后生活质量得到改善，满意度更高。将生活质量测评引入中国MS研究，或可让神经科医师更为全面地了解DMT的临床疗效及患者对其的主观评价，也为监管机构评估MS药物疗效提供了颇具价值的视角。“,”Multiple sclerosis (MS) is a chronic and progressive disease. Patients with MS experience symptoms that result in a decline in physical and psychological function, which has a negative and serious impact on their quality of life (QoL). QoL, which provides a broad and subjective measure of the disease as well as treatment impact, is one of the frequently used patient reported outcome (PRO) measurements. The Teri-PRO study investigated the overall satisfaction of patients with MS treated with teriflunomide by using the Treatment Satisfaction Questionnaire. The results showed that greater patient satisfaction was reported when converting injectable disease modifying therapy (DMT) to oral treatment with teriflunomide. The introduction of QoL assessment into MS research in China enables neurologists to comprehensively understand the clinical efficacy of DMT and the subjective evaluation, and provides a valuable perspective for regulatory authorities to evaluate MS medication.